Latest news with #SEK511.61
Yahoo
24-03-2025
- Business
- Yahoo
March 2025's European Stocks Possibly Priced Below Their Estimated Value
As the pan-European STOXX Europe 600 Index ended higher, breaking a streak of losses, investors are cautiously optimistic amid mixed signals from global economic policies and trade tensions. In this environment, identifying stocks that may be undervalued can offer potential opportunities for those looking to navigate the complexities of market fluctuations and economic uncertainties. Name Current Price Fair Value (Est) Discount (Est) Absolent Air Care Group (OM:ABSO) SEK260.00 SEK511.61 49.2% Romsdal Sparebank (OB:ROMSB) NOK130.30 NOK259.93 49.9% Vimi Fasteners (BIT:VIM) €0.97 €1.91 49.2% CTT Systems (OM:CTT) SEK221.00 SEK440.81 49.9% Comet Holding (SWX:COTN) CHF233.00 CHF464.46 49.8% Net Insight (OM:NETI B) SEK4.82 SEK9.58 49.7% Deutsche Beteiligungs (XTRA:DBAN) €26.55 €53.05 50% dormakaba Holding (SWX:DOKA) CHF681.00 CHF1356.93 49.8% Melhus Sparebank (OB:MELG) NOK167.04 NOK329.29 49.3% Neosperience (BIT:NSP) €0.532 €1.06 49.7% Click here to see the full list of 212 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's review some notable picks from our screened stocks. Overview: Altri SGPS is a company that produces and sells cellulosic fibers both in Portugal and internationally, with a market cap of €1.28 billion. Operations: The company's revenue primarily comes from the production and commercialization of cellulosic fibers, totaling €710.40 million. Estimated Discount To Fair Value: 43.1% Altri SGPS is trading at €6.23, significantly below its estimated fair value of €10.95, suggesting it may be undervalued based on cash flows. Recent earnings results show strong net income growth from €42.8 million to €107.2 million year-over-year, highlighting robust profitability despite revenue growing slower than 20% annually. However, interest payments are not well covered by earnings and the dividend track record is unstable, which could pose risks to potential investors seeking stability in returns. The analysis detailed in our Altri SGPS growth report hints at robust future financial performance. Click here to discover the nuances of Altri SGPS with our detailed financial health report. Overview: BlueNord ASA is an oil and gas company engaged in the exploration, development, and production of hydrocarbon resources across Norway, Denmark, the Netherlands, and the United Kingdom with a market cap of NOK17.60 billion. Operations: The company's revenue is primarily generated from its Oil & Gas - Exploration & Production segment, amounting to $702.30 million. Estimated Discount To Fair Value: 39.3% BlueNord ASA, trading at NOK664, is significantly below its estimated fair value of NOK1094.56, indicating it is undervalued based on cash flows. Despite a recent net loss of US$70.8 million for 2024 and interest payments not well covered by earnings, the company is forecast to achieve high profitability growth over the next three years. Recent operational challenges at Tyra II are expected to be resolved soon, potentially enhancing production efficiency and financial performance going forward. Our earnings growth report unveils the potential for significant increases in BlueNord's future results. Click to explore a detailed breakdown of our findings in BlueNord's balance sheet health report. Overview: Bonesupport Holding AB (publ) is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes across Europe, North America, and internationally, with a market cap of SEK21.85 billion. Operations: The company's revenue primarily comes from its Pharmaceuticals segment, generating SEK898.73 million. Estimated Discount To Fair Value: 42.8% Bonesupport Holding, trading at SEK331.8, is significantly undervalued with an estimated fair value of SEK580.34 based on cash flow analysis. Despite a decrease in net profit margin from 41.5% to 14.9% over the past year, its earnings and revenue are forecast to grow substantially faster than the Swedish market over the next three years. Recent positive study results for CERAMENT products may bolster future growth prospects and enhance profitability further. Upon reviewing our latest growth report, Bonesupport Holding's projected financial performance appears quite optimistic. Unlock comprehensive insights into our analysis of Bonesupport Holding stock in this financial health report. Click through to start exploring the rest of the 209 Undervalued European Stocks Based On Cash Flows now. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTLS:ALTR OB:BNOR and OM:BONEX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
24-03-2025
- Business
- Yahoo
European Stocks Estimated To Be Trading Below Intrinsic Value By Up To 47.5%
As European markets navigate a complex landscape marked by hopes of increased government spending and trade-related uncertainties, the pan-European STOXX Europe 600 Index has managed to snap two weeks of losses with a modest gain. Against this backdrop, identifying stocks trading below their intrinsic value can be particularly appealing to investors seeking opportunities in an environment where central banks are balancing growth concerns and inflation risks. Name Current Price Fair Value (Est) Discount (Est) Absolent Air Care Group (OM:ABSO) SEK260.00 SEK511.61 49.2% Romsdal Sparebank (OB:ROMSB) NOK130.30 NOK259.93 49.9% Vimi Fasteners (BIT:VIM) €0.97 €1.91 49.2% CTT Systems (OM:CTT) SEK221.00 SEK440.81 49.9% Comet Holding (SWX:COTN) CHF233.00 CHF464.46 49.8% Net Insight (OM:NETI B) SEK4.82 SEK9.58 49.7% Deutsche Beteiligungs (XTRA:DBAN) €26.55 €53.05 50% dormakaba Holding (SWX:DOKA) CHF681.00 CHF1356.93 49.8% Melhus Sparebank (OB:MELG) NOK167.04 NOK329.29 49.3% Neosperience (BIT:NSP) €0.532 €1.06 49.7% Click here to see the full list of 212 stocks from our Undervalued European Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Lectra SA offers industrial intelligence solutions for the fashion, automotive, furniture markets, and other industries globally with a market cap of €1.05 billion. Operations: The company's revenue segments include €176.10 million from the Americas, €131.53 million from the Asia-Pacific region, and €219.05 million from EMEA (Europe, Middle East, and Africa). Estimated Discount To Fair Value: 25.8% Lectra is trading 25.8% below its estimated fair value of €37.47, making it highly undervalued based on discounted cash flow analysis. Despite a slight decline in net income for 2024, earnings are forecast to grow significantly at 23.1% annually over the next three years, outpacing the French market's growth rate of 13%. Revenue is expected to increase by 6% per year, slightly above the market average. The growth report we've compiled suggests that Lectra's future prospects could be on the up. Dive into the specifics of Lectra here with our thorough financial health report. Overview: MedinCell S.A. is a pharmaceutical company based in France that specializes in developing long-acting injectables across various therapeutic areas, with a market capitalization of €497.23 million. Operations: The company's revenue segment is derived entirely from its pharmaceuticals division, amounting to €13.20 million. Estimated Discount To Fair Value: 47.5% MedinCell is trading 47.5% below its estimated fair value of €28.62, indicating it is significantly undervalued based on discounted cash flow analysis. The company anticipates revenue growth of 68.4% annually, surpassing the French market's growth rate, with profitability expected within three years. Recent strategic developments include a €42.9 million equity offering and a $5 million milestone payment from Teva for olanzapine LAI's clinical trial completion, enhancing its financial position amidst robust growth forecasts. According our earnings growth report, there's an indication that MedinCell might be ready to expand. Click here and access our complete balance sheet health report to understand the dynamics of MedinCell. Overview: Cint Group AB (publ) offers software solutions for digital insights and research technology on a global scale, with a market cap of SEK2.68 billion. Operations: Cint Group AB generates revenue through its Cint Exchange segment, contributing €116.82 million, and Media Measurement segment, which adds €49.37 million. Estimated Discount To Fair Value: 17.1% Cint Group, trading at SEK7.55, is undervalued compared to its fair value estimate of SEK9.11, though not significantly. Despite recent shareholder dilution and a volatile share price, the company is expected to achieve profitability within three years with revenue growth outpacing the Swedish market at 5.5% annually. Recent financial results show improved net income and reduced losses year-over-year, supported by a SEK584 million follow-on equity offering to bolster cash reserves amidst strategic initiatives. In light of our recent growth report, it seems possible that Cint Group's financial performance will exceed current levels. Unlock comprehensive insights into our analysis of Cint Group stock in this financial health report. Delve into our full catalog of 212 Undervalued European Stocks Based On Cash Flows here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:LSS ENXTPA:MEDCL and OM:CINT. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
